Novo Nordisk Lifts Guidance as Wegovy Pill Outpaces Injections — and Analysts Can't Agree on What It's Worth
Published on 11/06/2026 at 22:01 | Editorial boerse-global.de
Novo Nordisk raised its full-year 2026 guidance on Wednesday, and the market's response has been a study in disagreement. Two research houses lifted their price targets the same day — and landed on opposite recommendations.
The Danish drugmaker now expects adjusted sales growth and adjusted operating profit growth, both at constant currencies, of between -2% and +2%. That is a marked improvement on the previous range of -6% to 0%, and the company credits higher expectations for its GLP-1 products.
A quarter where profit outran revenue
Third-quarter 2026 net sales came in at DKK 79,195 million, up 4% at constant exchange rates. Adjusted operating profit reached DKK 31,720 million, a constant-currency gain of 27% — meaning earnings grew roughly seven times faster than the top line.
That divergence sits at the heart of the analyst debate. SB1 Markets lifted its target to DKK 345 from DKK 335 and reiterated its buy rating, offering no additional rationale for the move. Bernstein took a different view of the same numbers, keeping its negative rating while raising its target to DKK 223 from DKK 203.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analyst Justin Smith's estimates at Bernstein remain as much as 17% below the analyst consensus despite the increase. The brokerage points to market-share losses in injectable GLP-1 treatments and weaker profitability as factors capping the business outlook — headwinds it says outweigh the improved guidance.
The pill is the counterargument
The case for optimism rests on the oral franchise. The Wegovy tablet generated DKK 5.39 billion in third-quarter 2026 revenue, according to BioPharma Dive, against an analyst consensus of DKK 4.96 billion. The injectable version, by contrast, saw its US sales decline in the same quarter at constant exchange rates.
Whether the tablet can offset share losses and margin pressure is the valuation question both notes circle. Sustained demand and a more profitable product mix would vindicate SB1's stance; persistent margin erosion would support Bernstein's caution.
Beyond the medicine: the distribution question
Access to patients is emerging as a separate battleground. Financial commentator Niels Lunde describes a commercial ecosystem of digital sales channels, new payment pathways and partners built around Wegovy. CEO Mike Doustdar said Wednesday that NovoCare and its partners should also be deployed in any future launch of CagriSema, potentially extending the distribution structure beyond Wegovy.
Lunde attaches a condition to that thesis: the model must create a competitive advantage rather than simply add cost. Broader access strengthens Novo's case if it converts into profitable demand; continued margin pressure would reinforce Bernstein's more cautious read.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Semaglutide data and a busy November
Also on Wednesday, Novo released real-world findings on semaglutide 2.4 mg in adults with MASH, focusing in part on weight change versus treatment with resmetirom. In the PLATINUM-Truveta study, patients on semaglutide lost an average of 18.9 pounds over six months, against 5.6 pounds on resmetirom.
Novo stressed that both studies presented were retrospective and based on observational data, so their results cannot establish causal relationships.
More data is due at ObesityWeek 2026, running November 14–17 in Washington. Novo has announced 26 presentations, including on the investigational CagriSema and on real-world experience with the Wegovy pill.
Ad
Novo Nordisk Stock: New Analysis - 6 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
